Cancer Biology and Signal Transduction GSK 3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms , Including p 53 and Wnt Signaling

Neuroblastoma is an embryonal tumor accounting for approximately 15%of childhood cancer deaths. There exists a clinical need to identify novel therapeutic targets, particularly for treatment-resistant forms of neuroblastoma. Therefore, we investigated the role of the neuronal master regulator GSK3 in controlling neuroblastoma cell fate. We identified novel GSK3-mediated regulation of MYC (c-MYC and MYCN) mRNA levels, which may have implications for numerous MYC-driven cancers. In addition, we showed that certain GSK3 inhibitors induced large-scale cell death in neuroblastoma cells, primarily through activating apoptosis. mRNA-seq of GSK3 inhibitor–treated cells was performed and subsequent pathway analysis revealed that multiple signaling pathways contributed to the loss of neuroblastoma cell viability. The contribution of two of the signalingpathwayshighlightedby themRNA-seq analysiswas functionally validated. Inhibition of the p53 tumor suppressor partly rescued the cell death phenotype, whereas activation of canonical Wnt signaling contributed to the loss of viability, in a p53-independent manner. Two GSK3 inhibitors (BIO-acetoxime and LiCl) and one small-molecule Wnt agonist (Wnt Agonist 1) demonstrated therapeutic potential for neuroblastoma treatment. These inhibitors reduced the viability of numerous neuroblastoma cell lines, even those derived from high-risk MYCN-amplified metastatic tumors, for which effective therapeutics are currently lacking. Furthermore, although LiCl was lethal to neuroblastoma cells, it did not reduce the viability of differentiated neurons. Taken together our data suggest that these small molecules may hold potential as effective therapeutic agents for the treatment of neuroblastoma and other MYC-driven cancers. Mol Cancer Ther; 13(2); 454–67. 2013 AACR.

[1]  M. Ergüven,et al.  Notch Signaling–related Therapeutic Strategies With Novel Drugs in Neuroblastoma Spheroids , 2014, Journal of pediatric hematology/oncology.

[2]  F. Westermann,et al.  RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance , 2013, Oncogene.

[3]  F. Westermann,et al.  Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis. , 2013, Human molecular genetics.

[4]  Nathalie Harder,et al.  MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells. , 2013, Cancer letters.

[5]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[6]  F. Speleman,et al.  MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells , 2013, Oncogene.

[7]  Davis J. McCarthy,et al.  Count-based differential expression analysis of RNA sequencing data using R and Bioconductor , 2013, Nature Protocols.

[8]  R. Stallings,et al.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis , 2013, Pediatric Surgery International.

[9]  M. Martindale,et al.  A Framework for the Establishment of a Cnidarian Gene Regulatory Network for “Endomesoderm” Specification: The Inputs of ß-Catenin/TCF Signaling , 2012, PLoS genetics.

[10]  Jan Koster,et al.  Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification , 2012, Proceedings of the National Academy of Sciences.

[11]  James S Goydos,et al.  Non-Canonical Smads Phosphorylation Induced by the Glutamate Release Inhibitor, Riluzole, through GSK3 Activation in Melanoma , 2012, PloS one.

[12]  R. Stallings,et al.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression , 2012, Nature Genetics.

[13]  Sandeep R. Bhave,et al.  GSK-3β: A Bifunctional Role in Cell Death Pathways , 2012, International journal of cell biology.

[14]  T. Stuhlmiller,et al.  Current perspectives of the signaling pathways directing neural crest induction , 2012, Cellular and Molecular Life Sciences.

[15]  David J. Duffy,et al.  A heat shock protein and Wnt signaling crosstalk during axial patterning and stem cell proliferation. , 2012, Developmental biology.

[16]  Davis J. McCarthy,et al.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.

[17]  K. Matthay,et al.  Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma , 2012, Science Translational Medicine.

[18]  E. Yang,et al.  Emerging Roles of Glycogen Synthase Kinase 3 in the Treatment of Brain Tumors , 2011, Front. Mol. Neurosci..

[19]  Dk Thotala,et al.  GSK3B (glycogen synthase kinase 3 beta) , 2011 .

[20]  Giovanni Parmigiani,et al.  Integrating diverse genomic data using gene sets , 2011, Genome Biology.

[21]  David J. Duffy,et al.  Induced stem cell neoplasia in a cnidarian by ectopic expression of a POU domain transcription factor , 2011, Development.

[22]  J. Jester,et al.  Inhibition of TGFBIp expression by lithium: implications for TGFBI-linked corneal dystrophy therapy. , 2011, Investigative ophthalmology & visual science.

[23]  F. Wandosell,et al.  Deconstructing GSK-3: The Fine Regulation of Its Activity , 2011, International journal of Alzheimer's disease.

[24]  David J. Duffy,et al.  Modulation of COUP-TF Expression in a Cnidarian by Ectopic Wnt Signalling and Allorecognition , 2011, PloS one.

[25]  David J. Duffy,et al.  Wnt signaling promotes oral but suppresses aboral structures in Hydractinia metamorphosis and regeneration , 2010, Development.

[26]  P. Lonergan,et al.  Identification and regulation of glycogen synthase kinase-3 during bovine embryo development. , 2010, Reproduction.

[27]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[28]  D. Geerts,et al.  MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3. , 2010, Cancer letters.

[29]  W. Weiss,et al.  Myc proteins as therapeutic targets , 2010, Oncogene.

[30]  R. Goodman,et al.  A β-catenin/TCF-coordinated chromatin loop at MYC integrates 5′ and 3′ Wnt responsive enhancers , 2009, Proceedings of the National Academy of Sciences.

[31]  Lingyi Chen,et al.  A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells , 2009, Proceedings of the National Academy of Sciences.

[32]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[33]  B. Doble,et al.  GSK-3 is a master regulator of neural progenitor homeostasis , 2009, Nature Neuroscience.

[34]  Rainer König,et al.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas , 2008, Genome Biology.

[35]  S. Pastorino,et al.  Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. , 2008, Cancer research.

[36]  J. Jordán,et al.  A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286 , 2008, Journal of cellular and molecular medicine.

[37]  R. Mayor,et al.  Molecular analysis of neural crest migration , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[38]  Z. Marinova,et al.  Synergistic Neuroprotective Effects of Lithium and Valproic Acid or Other Histone Deacetylase Inhibitors in Neurons: Roles of Glycogen Synthase Kinase-3 Inhibition , 2008, The Journal of Neuroscience.

[39]  R. Versteeg,et al.  Dickkopf‐3 expression is a marker for neuroblastic tumor maturation and is down‐regulated by MYCN , 2007, International journal of cancer.

[40]  B. Doble,et al.  Functional redundancy of GSK-3α and GSK-3β in wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines , 2007 .

[41]  D. Rowitch,et al.  Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. , 2006, Cancer research.

[42]  K. Heidenreich,et al.  Endoplasmic reticulum stress and trophic factor withdrawal activate distinct signaling cascades that induce glycogen synthase kinase-3β and a caspase-9-dependent apoptosis in cerebellar granule neurons , 2006, Molecular and Cellular Neuroscience.

[43]  Jun Liu,et al.  A small-molecule agonist of the Wnt signaling pathway. , 2005, Angewandte Chemie.

[44]  G. Raguénez,et al.  Low expression of Wnt-5a gene is associated with high-risk neuroblastoma , 2005, Oncogene.

[45]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[46]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[47]  R. Arceci.  Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma , 2008 .

[48]  K. Matthay,et al.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. , 1999, The New England journal of medicine.

[49]  D. Hallahan,et al.  LABORATORY INVESTIGATION – HUMAN/ANIMAL TISSUE GSK-3b inhibition promotes cell death, apoptosis, and in vivo , 2022 .